Sartorius AG

Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux

Tuesday, May 4, 2021 - 12:23pm

of the French Commercial Code, and the AMF decision no.

Key Points: 
  • of the French Commercial Code, and the AMF decision no.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

First-quarter results of Sartorius Stedim Biotech

Wednesday, April 21, 2021 - 6:00am

(All figures in sales revenue growth in constant currencies)\nThe Sartorius Stedim Biotech Group has a very sound balance sheet and financial key figures.

Key Points: 
  • (All figures in sales revenue growth in constant currencies)\nThe Sartorius Stedim Biotech Group has a very sound balance sheet and financial key figures.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.\nThis is a translation of the original French-language press release.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.
  • The original French press release is the legally binding version.\nFollow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn.\nDr.

Resolutions of the Annual Shareholders' Meeting of Sartorius AG

Friday, March 26, 2021 - 3:47pm

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.

Key Points: 
  • The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.
  • The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.
  • The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies.
  • At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60manufacturing and sales sites, serving customers around the globe.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Wednesday, March 24, 2021 - 2:44pm

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech increases its full-year 2021 guidance

Thursday, March 18, 2021 - 7:13am

AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.

Key Points: 
  • AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.
  • The major part of the expected additional business is related to the coronavirus pandemic as many products of Sartorius Stedim Biotech are used for manufacturing vaccines.
  • Sartorius Stedim Biotech will publish first quarter 2021 figures as scheduled on April 21, 2021.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

Bioreactor Market Revenue to Cross USD 16 Bn by 2027: Global Market Insights Inc.

Tuesday, March 16, 2021 - 7:00am

Rising demand for therapeutic drugs in biopharmaceutical industry will spur the bioreactor market growth.

Key Points: 
  • Rising demand for therapeutic drugs in biopharmaceutical industry will spur the bioreactor market growth.
  • Moreover, growing research and development expenditure by the government and major market players will augment the revenue growth.
  • Yeast cells segment in the bioreactor market is expected to foresee lucrative growth in the coming years.
  • Major companies operating in the global bioreactor market include Cytiva, Merck Group, Sartorius Stedim Biotech Group and Eppendorf.

Sartorius Stedim Biotech looks back on a very successful 2020 and expects further strong growth

Thursday, February 18, 2021 - 12:00pm

Due to very high organic growth, Sartorius Stedim Biotech is extending and accelerating the expansion of production capacities.

Key Points: 
  • Due to very high organic growth, Sartorius Stedim Biotech is extending and accelerating the expansion of production capacities.
  • (All sales revenue growth figures in constant currencies)
    Sartorius Stedim Biotech invested substantially in expanding its capacity in 2020 in order to meet high demand.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.

Sartorius Stedim Biotech SA: Information on Document Availability

Thursday, February 18, 2021 - 8:01am

It contains the following information:

Key Points: 
  • It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2020
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Resolutions of the Supervisory Board of Sartorius AG

Thursday, February 11, 2021 - 6:58pm

GTTINGEN, Germany, Feb. 11, 2021 /PRNewswire/ -- The Supervisory Board of Sartorius AG resolved at its meeting today to approve an early extension of the appointments of Ren Fber as a member of the Executive Board and Head of the BioprocessSolutionsDivision, as well as of Gerry Mackay as a member of the Executive Board and Headofthe Lab Products & Services Division.

Key Points: 
  • GTTINGEN, Germany, Feb. 11, 2021 /PRNewswire/ -- The Supervisory Board of Sartorius AG resolved at its meeting today to approve an early extension of the appointments of Ren Fber as a member of the Executive Board and Head of the BioprocessSolutionsDivision, as well as of Gerry Mackay as a member of the Executive Board and Headofthe Lab Products & Services Division.
  • Ren Fber (45) has been working for Sartorius since 2002 and has been an Executive Board member of SartoriusAG since January 2019.
  • Gerry Mackay (58) joined Sartorius in 2015 through the acquisition of BioOutsource and has been an Executive Board member of SartoriusAG also since January2019.
  • The Supervisory Board accepted Gerry Mackay's request to extend his appointment only by two years until December31, 2023, due to his private plans for the future.

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.68 euros per share to Annual Shareholders' Meeting

Friday, February 5, 2021 - 4:52pm

AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.

Key Points: 
  • AUBAGNE, France, Feb. 5, 2021 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today's meeting to submit a proposal to the combined Annual General Shareholders' Meeting on March 24, 2021, to pay a dividend for fiscal 2020 of 0.68 euros per share.
  • This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.